Trial Profile
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Jan 2024
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms CheckMate 227
- Sponsors Bristol-Myers Squibb; Ono Pharmaceutical
- 12 Sep 2023 Results of updated outcomes at 6 years minimum follow-up, including association of OS with response/tumor burden reduction and HRQoL, presented at the 24th World Conference on Lung Cancer
- 11 Sep 2023 Primary endpoint (Overall survival (OS) [Part Ib]) has been met, according to Bristol-Myers Squibb Media Release.
- 11 Sep 2023 According to a Bristol-Myers Squibb Media Release, ollow-up results will be featured in an oral presentation (Abstract #OA14.03) and have been selected for the official press program at the IASLC 2023 World Conference on Lung Cancer (#WCLC23) hosted by the International Association for the Study of Lung Cancer on September 11, 2023, from 2:32 a.m. to 2:42 a.m. EDT / 2:32 p.m. to 2:42 p.m. SGT.